79,609 Haleon PLC Sponsored ADR $HLN Shares Acquired by Provenance Wealth Advisors LLC

Provenance Wealth Advisors LLC lifted its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 26,536.3% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 79,909 shares of the company’s stock after acquiring an additional 79,609 shares during the period. Provenance Wealth Advisors LLC’s holdings in Haleon were worth $719,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of HLN. Parkside Financial Bank & Trust increased its holdings in shares of Haleon by 20.4% during the second quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company’s stock valued at $58,000 after acquiring an additional 1,055 shares in the last quarter. Personal CFO Solutions LLC boosted its stake in Haleon by 11.5% in the 1st quarter. Personal CFO Solutions LLC now owns 15,673 shares of the company’s stock worth $157,000 after purchasing an additional 1,620 shares in the last quarter. Sterling Capital Management LLC boosted its stake in Haleon by 1.9% in the 3rd quarter. Sterling Capital Management LLC now owns 88,039 shares of the company’s stock worth $792,000 after purchasing an additional 1,624 shares in the last quarter. Diversify Advisory Services LLC grew its position in Haleon by 7.7% during the 3rd quarter. Diversify Advisory Services LLC now owns 24,023 shares of the company’s stock worth $239,000 after purchasing an additional 1,711 shares during the last quarter. Finally, Allen Capital Group LLC grew its position in Haleon by 14.5% during the 1st quarter. Allen Capital Group LLC now owns 13,628 shares of the company’s stock worth $136,000 after purchasing an additional 1,729 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Price Performance

NYSE:HLN opened at $9.24 on Thursday. Haleon PLC Sponsored ADR has a one year low of $8.38 and a one year high of $11.28. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.52 and a current ratio of 0.69. The firm has a market cap of $40.69 billion, a price-to-earnings ratio of 23.69, a PEG ratio of 2.07 and a beta of 0.15. The firm’s fifty day moving average is $9.47 and its two-hundred day moving average is $9.76.

Analyst Ratings Changes

HLN has been the topic of a number of recent analyst reports. Berenberg Bank restated a “buy” rating on shares of Haleon in a research note on Wednesday, August 5th. Jefferies Financial Group downgraded shares of Haleon from a “buy” rating to a “hold” rating in a research note on Wednesday. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Haleon in a research note on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft raised shares of Haleon from a “sell” rating to a “hold” rating in a report on Friday, October 30th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Haleon in a research report on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Haleon currently has an average rating of “Moderate Buy” and a consensus target price of $4.90.

Haleon Profile

Haleon plc (NYSE: HLN) is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.

Haleon’s well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company’s products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.

Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.